GovChime
Notice ID: 2743259f47984423a9ee82a65d313762Special NoticeArchived

NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022D00017 WITH THE EMMES COMPANY, LLC.

Archived on January 14, 2026. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
3:00 PM EST
Posted
December 15, 2025
Notice type
Special Notice
Set-aside
No Set aside used
NAICS
541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIDA
Place of performance
Rockville, Maryland, 20850
Last updated
Nov 5, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
75N95022D00017
Notice ID
2743259f47984423a9ee82a65d313762

Description

INTRODUCTION

PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION.   

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022D00017 (NIDA REF. NO. N01DA-22-2253) WITH THE EMMES COMPANY, LLC. 

The National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) and the Center for the Clinical Trials Network (CTN) intends to modify the Single Award Indefinite Delivery, Indefinite Quantity (IDIQ) Contract No. 75N95022D00017  “CTN Data, Statistics, and Clinical Trial Support Center” (DSC6) to increase the maximum dollar amount of services the Government will acquire under this contracts by $13,158,436 million from $31,154,646 to $44,313,082 during the five (5) year ordering period from September 5, 2022, to September 4, 2027; there are no other changes.

The increase to the cost ceiling will allow for the continuation of work begun under the DSC6 contract and prevent any delays or disruption of support services for ongoing and upcoming clinical trials while a new contract is properly planned and competed.  To support efforts to address the national opioid public health crisis, the CTN through this contract modification also address a significant expansion of its opioid research portfolio. 

The DSC6 contract provides contract support services in the following areas:

  • Establish and administer state-of-the-art, secured web-based systems for the collection, storage, management, quality assurance, and reporting of study data as well as systems to facilitate the collection and management of participant and site level electronic health records data.
  • Assist in the design and analysis of clinical trials, including the development of the statistical sections of protocols, study design, randomization and stratification methods, power and sample size calculations, interim monitoring and analysis plans, and data analytic plans.
  • Review and monitor the quality of study data including the development and management of a computerized data monitoring system that executes quality assurance and quality control procedures to evaluate accuracy, timeliness and completeness of data submitted by the clinical sites, including verification of the clinical and laboratory data used to determine that study participants have reached protocol-defined endpoints.
  • Monitor trial performance and progress and maintain a secure web-based clinical trial performance monitoring system to track key trial performance metrics (e.g. key dates, recruitment, availability of primary outcomes, missing data, etc.).
  • Coordinate meetings of study Data and Safety Monitoring Boards (DSMB) to include the preparation and presentation of reports on safety, data integrity, and site performance as well as coordination of meeting sites, materials, travel support, etc.).
  • Participate in relevant committee and subcommittee meetings including representation by the contract Principal Investigator on the CTN Steering Committee and representation by other senior data and statistical experts on other relevant CTN committees, subcommittees and workgroups.

NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE

The intended procurement is classified under NAICS code 541715 with a small business size standard of 1,000 employees

REGULATORY AUTHORITY

The resultant modification will include all applicable provisions and clauses of the Federal Acquisition Regulation (FAR) in effect through the Federal Acquisition Circular (FAC) 2025-06 with effective date 10/01/2025.

STATUTORY AUTHORITY

This acquisition is conducted as non-competitive under the authority of 41 U.S.C. 3304(a)(1) under provisions of the statutory authority of FAR Subpart 6.302-1.

DESCRIPTION

Background
NIDA’s CTN was established in 1999 to bridge the gap between research and practice to improve treatment of substance use disorders (SUD) nationwide. CTN conducts clinical trials in sites located across the nation and in other countries. These are usually studies of behavioral, pharmacological, and integrated behavioral and pharmacological treatment interventions in rigorous, clinical trials to determine efficacy, effectiveness, practicality, and feasibility across a broad range of treatment settings and diversified patient populations and to transfer research results to physicians, clinicians, providers, and patients.  These studies are typically Phase III clinical trials, but can also include Phase I, Phase II, Phase IV, and/or registry trials or surveys. The CTN seeks to address critical research questions with direct relevance to clinical practice and the needs of patients. 

Over the last twenty-five years, the CTN’s research infrastructure and agenda have evolved to reflect the changing landscape of the SUD treatment community, transformation of health care systems, and emerging scientific advancements.  The CTN has been engaging providers in general medical settings and healthcare systems, and in 2015 the Network built upon and expanded its research portfolio encouraging adoption of innovative bioinformatics approaches, new technology, and "learning healthcare system" principles to enhance the efficiency of SUD clinical research and clinical care.

The CTN conducts clinical trials in sites located across the nation and in other countries.  These are usually studies of behavioral, pharmacological, and integrated behavioral and pharmacological treatment interventions in rigorous, clinical trials to determine efficacy, effectiveness, practicality, and feasibility across a broad range of treatment settings and diversified patient populations and to transfer research results to physicians, clinicians, providers, and patients.  These studies are typically Phase III clinical trials, but can also include Phase I, Phase II, Phase IV, and/or registry trials or surveys.  More information on the CTN and the CTN’s research portfolio is available at https://www.drugabuse.gov/about-nida/organization/cctn/ctn. 

Goals and Objectives

Contract No. 75N95022D00017  provides data and clinical research support and resources to the CTN in managing and carrying out multiple trials in drug abuse research, which in part includes the NIH HEAL Initiative to address the national opioid public health crisis.  The Contractor provides support for systems, procedures, and expertise in data management, statistical support, and information support and services.  The systems are then used to support data collection, data analysis, document management, information exchange, scientific discovery efforts and clinical evaluation of promising new anti-addiction therapies and companion behavioral interventions to further NIDA’s mission.  The project includes the following tasks:

  • Establish and administer state-of-the-art, secured web-based systems for the collection, storage, management, quality assurance, and reporting of study data as well as systems to facilitate the collection and management of participant and site level electronic health records data.
  • Assist in the design and analysis of clinical trials, including the development of the statistical sections of protocols, study design, randomization and stratification methods, power and sample size calculations, interim monitoring and analysis plans, and data analytic plans.
  • Review and monitor the quality of study data including the development and management of a computerized data monitoring system that executes quality assurance and quality control procedures to evaluate accuracy, timeliness and completeness of data submitted by the clinical sites, including verification of the clinical and laboratory data used to determine that study participants have reached protocol-defined endpoints.
  • Monitor trial performance and progress and maintain a secure web-based clinical trial performance monitoring system to track key trial performance metrics (e.g. key dates, recruitment, availability of primary outcomes, missing data, etc.).
  • Coordinate meetings of study Data and Safety Monitoring Boards (DSMB) to include the preparation and presentation of reports on safety, data integrity, and site performance as well as coordination of meeting sites, materials, travel support, etc.).
  • Participate in relevant committee and subcommittee meetings including representation by the contract Principal Investigator on the CTN Steering Committee and representation by other senior data and statistical experts on other relevant CTN committees, subcommittees and workgroups.

Period of Performance

The IDIQ contract proposed for modification has an ordering period of September 5, 2022 to September 4, 2027 which remains unchanged.

CLOSING STATEMENT

This synopsis is not a request for competitive proposals and the Government is not committed to award a contract pursuant to this announcement.  However, interested entities may respond by identifying their interest, submitting capability statements, and or submitting objections to the proposed contract modification.  The Government will consider responses; however, a determination by the Government to proceed with the proposed contract modification is solely within the discretion of the Government.

Any potential offeror must have an active registration in the System for Award Management (SAM) www.sam.gov. In addition, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response.

A determination by the Government not to compete this proposed modification based upon responses to this notice is solely within the discretion of the Government.  The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

All responses must be received by 3:00 p.m. Eastern Daylight Time, Tuesday, December 30, 2025, and reference notice number 75N95022D00017.  Responses must be submitted electronically to Llakim Dubroff, Contract Specialist, at Llakim.Dubroff@nih.gov and Josh Lazarus at josh.lazarus@nih.gov.  Fax responses will not be accepted.

Contracting Office Address:
National Institutes of Health
National Institute on Drug Abuse
Office of Acquisitions
c/o 3WFN MSC 6012
301 N Stonestreet Ave
Bethesda, MD 20892

All responsible sources may submit a capability statement which shall be considered by the agency.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

No documents available.

Lifecycle

  1. 2
    Version 2Award NoticeArchived

    Data, Statistics, and Clinical Trial Support Center (DSC6)

    Notice ec99c44f5e88491bb9e45cddbf2cd625 on SAM.gov

  2. 5
    Version 5Special NoticeArchivedCurrent

    Type changed from Award Notice to Special Notice

    NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022D00017 WITH THE EMMES COMPANY, LLC.

    Notice 2743259f47984423a9ee82a65d313762 on SAM.gov

Other notices for this solicitation

  1. AwardedOct 17, 2022

    Data, Statistics, and Clinical Trial Support Center (DSC6)

    Notice 6b62845cbd304cef809e3958eda645cc on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
This is a SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified business sources; (2) whether they are small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses); (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) whether commercials sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method. This notice is issued to help determine the appropriate acquisition method to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. The National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC) and National Institutes of Health (NIH) is seeking Capability Statements from business organizations with the demonstrated capability of providing service to support NIDA DTMC with the synthesis and distribution of drugs of abuse and related compounds. BACKGROUND AND OBJECTIVES: The National Institute on Drug Abuse (NIDA) is seeking capability statements from businesses with the capability to synthesize and distribute drugs of abuse and related compounds. The NIDA Drug Supply Program has played an important role in promoting and supporting the substance use research by providing a wide variety of authentic, pure, controlled and uncontrolled drugs and other chemical compounds (both unlabeled and labeled with deuterium, tritium, carbon -14, and iodine-125 isotopes) to the drug abuse research community for basic research. To continue to supply authentic and pure drugs and research chemicals, NIDA maintains the drug supply inventory, periodically check chemical purity and supply to research investigators according to the NIDA drug supply guidelines. Specifically, NIDA plans to continue to: (1) produce, acquire, synthesize and maintain several radio and deuterium labeled and unlabeled drugs of abuse and other chemical substances in its drug supply inventory and distribute them to research investigators upon approval; (2) analyze, test, establish, and maintain the purity of drugs of abuse, and other chemical compounds in the NIDA drug supply inventory and produce updated chemical data sheets; (3) to replenish existing drug supply inventory with depleted drugs and research compounds with the synthesis or acquisition of depleted drug/chemical substances routinely; (4) to identify, acquire, and update the drug supply inventory with newly discovered chemical compounds useful for drug abuse research; (5) to use, maintain, and update the NIDA drug supply data base, known as Drug Inventory Supply Control System (DISCS); and (6) accept and process request packages from researchers; (7) Provide secure storage for all compounds and safe shipment of approved drugs/compounds to research investigators. Capable vendors must demonstrate the capability to receive the current inventory of hundreds of DEA controlled and uncontrolled drugs, other chemical compounds including peptides (opioid and related neuropeptides) in several kilogram quantities for immediate storage. Many of these compounds will require refrigeration. Some substances are in solution form and therefore require appropriate and secure storage to meet DEA requirements. Chemical compounds to be synthesized shall include new drugs, drug metabolites and other compounds as directed by NIDA. Specific compounds may include but not be limited to unlabeled compounds as well as compounds labeled with tritium, 125I, 14C, and deuterium and 13C. Representative classes of compounds shall include cannabinoids, hallucinogens, narcotics and antagonists, stimulants, depressants, peptides (opioid and related neuropeptides). All chemical compounds must be stored under optimum shelf‑life conditions and their purity maintained at not less than 95%. Re-purification must be carried out if chemical or radiochemical deterioration occurs. MANDATORY REQUIREMENTS: To handle controlled substances under the Controlled Substances Act of 1970, it is mandatory that the successful capable vendors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. INSTRUCTIONS: Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than November 20, 2026 at 1:00 PM EST. Respondents must provide clear and convincing documentation of their capability and experience with providing the personnel and services as specified in the tasks above. Also, information must be provided in sufficient details of the respondents’ (a) staff expertise, including their availability, experience, formal and other training; (b) current capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and other management capability; and (e) examples of prior completed Government contracts, references, and other related information. Each capability statement must include the respondent’s UEI number, organization name, and address. Each response should include the technical and administrative points of contact with, names, titles, addresses, telephone numbers, and e-mail addresses. The capability statement should clearly identify the size and type of business (e.g., 8(a), HubZone, Non-Profit, Other Than Small Business, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirement and in the capability statement paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages. The 10-page limit does not include the cover page, executive summary, resumes, or references, if requested. Any business concerns that believe they possess the capability necessary to successfully undertake the work described above must SUBMIT CAPABILITY STATEMENTS ELECTRONICALLY to the Contract Specialist, Shaun Rostad at Shaun.Rostad@nih.gov, NO LATER THAN 1:00 p.m. EST on November 20, 2026. The Subject line for the submission should include this Sources Sought Number, SAM.gov Unique Entity Identifier (UEI) and organization name. NIDA will not accept paper or faxed capability statements. THIS NOTICE IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. CONFIDENTIALITY. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
-Market Research11/20/2026
INTRODUCTION: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens. NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (https://aspr.hhs.gov/PHEMCE/2024-PHEMCE-SIP/Pages/default.aspx), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html). In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation. An offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of this BAA Solicitation, instructions regarding the proposal submission, and a description of the evaluation and award process. Please note, due to the competitive nature of the BAA Solicitation, the NIAID is unable to offer advice or feedback regarding an offeror’s specific technical approach. Offerors should exercise their professional judgment when compiling their proposals in line with the requirements and specifications of the BAA Solicitation. Research Area 001 - Vaccine Candidates: The objective is to develop vaccine candidates through an early phase clinical trial that use a needle free (i.e., alternative to classical needle and syringe, see below for description) route of delivery to protect against infections caused by viral pathogens that include but are not limited to respiratory and vector borne viruses. The scope of this vaccine research area includes the preclinical development of a needle free vaccine candidate, IND enabling studies, limited process development, Good Manufacturing Practice (GMP) compliant manufacturing, regulatory submissions to the U.S. Food and Drug Administration (FDA) and conduct of a Phase 1 or early Phase 2 clinical trial. The scope of work must include a clinical trial. Offerors must propose a single vaccine candidate for protection against a specific viral pathogen. The vaccine candidate may provide a breadth of protection against other viral strains or viruses. A strong justification is required to support (1) the proposed vaccine antigen and platform for the disease indication, (2) the use of a clinically relevant adjuvant (if needed), and (3) a clinically relevant needle free route of delivery. Research Area 002 - Therapeutic Candidates: The objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Infectious diseases caused by the following viruses, bacteria and fungi pathogens are targeted: Viral hemorrhagic fever viruses (e.g., EBOV, SUDV, MARV, LASV, hantavirus) https://www.cdc.gov/viral-hemorrhagic-fevers/about/index.html Encephalitic paramyxoviruses (e.g. hendra virus, nipah virus) Picornaviruses (broad spectrum approaches that include EV68, EV70 and coxsackie virus) At least two of the following (i.e., addressed with a broad spectrum antimicrobial): susceptible and carbapenem-resistant Enterobacteriaceae (CRE), susceptible and multidrug resistant (MDR) Pseudomonas aeruginosa, and susceptible and Carbapenem-resistant Acinetobacter (CRAB), with potential to improve patient outcomes in the clinic; Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales Adjunct medical interventions to support or enhance effectiveness of antimicrobial agents to address underlying pathology that is not resolved after clearance of pathogens, may be considered. Important notice to Offerors: For this Research Area, “therapeutic” activity means curing disease by eliminating or substantially reducing infective pathogens by administering antimicrobial pharmaceutical agents, with or without a host-directed therapy. Additionally, proposed therapeutic products should consider the impact on a healthy microbiome. Preventative treatments are not included in the scope of this Research Area. A therapeutic candidate refers to an advanced lead series, preclinical candidates, or a clinical candidate, that is a new chemical entity. This includes small molecules, natural products, nucleosides, or peptides of </= 40 amino acids, monoclonal antibodies, nanobodies, nanobody conjugate/fusion products, microbiome-based therapeutics or bacteriophages. Research Area 002 will support lead optimization, pre-clinical Investigational New Drug (IND) enabling studies, and Phase 1 clinical trials (or proof of concept Phase 2 clinical trials) of lead candidates with demonstrated therapeutic activities. This includes support for traditional, novel (e.g., small molecules) and non-traditional (e.g., including but not limited to phage, and host-directed) therapeutics for infectious diseases where patients lack effective interventions, as well as therapeutics that promote host-mediated resolution of disease. The scope of support differs depending on the developmental stage of the project being proposed, which is further discussed in the BAA Solicitation. Research Area 003 - In Vitro Diagnostics The objective of Research Area 003 is to develop innovative, technology platforms that will speed detection and identification of infectious viruses covering a broad panel of virus families, including viruses causing acute infections as well as those causing chronic infections. Technology platform innovation to achieve faster actionable sequencing results (approaching 2 hr) direct from primary clinical specimens, as well as more accessible workflow and configuration (i.e., point-of-care) are preferred. Furthermore, full sample-to-answer platform solutions are preferred. The system should accept specimen volumes from 0.5 to 5 milliliters (mL). The system should include nearly full automation (little or no hands-on activity after specimen has been loaded into system). Sample preparation components of the system should yield sufficient analyte recovery from a starting titer of 10-100 genomic copies per mL of biofluid for downstream analysis, including detection, identification, and characterization of the nucleic acid material. Innovations during platform development might include, for example: Automated sample prep for high recovery from low pathogen load. Faster specimen-to-answer for total test time <2 hours. Broad viral pathogen detection capability, covering one or more members of the priority pathogen families (see below). Targeted, or even untargeted pathogen detection and identification via long-read sequencing or other detection methods. Multiple specimen throughput per run for reduced cost. Analytical sensitivity approaching 5-50 genome copies per mL of starting biofluid. Assay reconfigurability to respond rapidly to a novel pathogen in days or weeks rather than months (i.e., agnostic diagnostic solution). Priority Pathogens The diagnostic test system must detect analytes from at least one, and preferably several, of the following agents and markers: Arenaviridae (e.g., Lassa virus) Phenuviridae (e.g., Rift Valley fever virus) Peribunyayviridae (e.g., Oropouche virus) Hantaviridae (e.g., Hantavirus) Nairoviridae (e.g., Crimean Congo Hemorrhagic fever virus) Filoviridae (e.g., Sudan virus, Ebola virus, Marburg virus) Flaviviridae (e.g., Hepatitis C virus, West Nile Virus) Paramyxoviridae (e.g., Nipah virus) Togaviridae (e.g., Chikungunya virus) Picornaviridae (e.g., Enterovirus) PROPOSAL SUBMISSION: Proposals Due Date and Time – December 8, 2026, 3:00 PM Eastern Time For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by any other method is not permitted. For directions on using eCPS, go to the website: https://ecps.nih.gov and thenclick on "How to Submit."
-Solicitation12/08/2026
This is a SMALL BUSINESS SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses); (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) whether commercials sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code 541715 should not submit a response to this notice. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. The National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC) and National Institutes of Health (NIH) is seeking Capability Statements from Small Business organizations with the demonstrated capability of providing service to support NIDA DTMC with the synthesis and distribution of drugs of abuse and related compounds. BACKGROUND AND OBJECTIVES: The National Institute on Drug Abuse (NIDA) is seeking capability statements from small businesses with the capability to synthesize and distribute drugs of abuse and related compounds. The NIDA Drug Supply Program has played an important role in promoting and supporting the substance use research by providing a wide variety of authentic, pure, controlled and uncontrolled drugs and other chemical compounds (both unlabeled and labeled with deuterium, tritium, carbon -14, and iodine-125 isotopes) to the drug abuse research community for basic research. To continue to supply authentic and pure drugs and research chemicals, NIDA maintains the drug supply inventory, periodically check chemical purity and supply to research investigators according to the NIDA drug supply guidelines. Specifically, NIDA plans to continue to: (1) produce, acquire, synthesize and maintain several radio and deuterium labeled and unlabeled drugs of abuse and other chemical substances in its drug supply inventory and distribute them to research investigators upon approval; (2) analyze, test, establish, and maintain the purity of drugs of abuse, and other chemical compounds in the NIDA drug supply inventory and produce updated chemical data sheets; (3) to replenish existing drug supply inventory with depleted drugs and research compounds with the synthesis or acquisition of depleted drug/chemical substances routinely; (4) to identify, acquire, and update the drug supply inventory with newly discovered chemical compounds useful for drug abuse research; (5) to use, maintain, and update the NIDA drug supply data base, known as Drug Inventory Supply Control System (DISCS); and (6) accept and process request packages from researchers; (7) Provide secure storage for all compounds and safe shipment of approved drugs/compounds to research investigators. Capable vendors must demonstrate the capability to receive the current inventory of hundreds of DEA controlled and uncontrolled drugs, other chemical compounds including peptides (opioid and related neuropeptides) in several kilogram quantities for immediate storage. Many of these compounds will require refrigeration. Some substances are in solution form and therefore require appropriate and secure storage to meet DEA requirements. Chemical compounds to be synthesized shall include new drugs, drug metabolites and other compounds as directed by NIDA. Specific compounds may include but not be limited to unlabeled compounds as well as compounds labeled with tritium, 125I, 14C, and deuterium and 13C. Representative classes of compounds shall include cannabinoids, hallucinogens, narcotics and antagonists, stimulants, depressants, peptides (opioid and related neuropeptides). All chemical compounds must be stored under optimum shelf‑life conditions and their purity maintained at not less than 95%. Re-purification must be carried out if chemical or radiochemical deterioration occurs. MANDATORY REQUIREMENTS: To handle controlled substances under the Controlled Substances Act of 1970, it is mandatory that the successful capable vendors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. INSTRUCTIONS: Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than November 20, 2026 at 1:00 PM EST. Respondents must provide clear and convincing documentation of their capability and experience with providing the personnel and services as specified in the tasks above. Also, information must be provided in sufficient details of the respondents’ (a) staff expertise, including their availability, experience, formal and other training; (b) current capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and other management capability; and (e) examples of prior completed Government contracts, references, and other related information. Each capability statement must include the respondent’s UEI number, organization name, and address. Each response should include the technical and administrative points of contact with, names, titles, addresses, telephone numbers, and e-mail addresses. The capability statement should clearly identify the size and type of business (e.g., 8(a), HubZone, Non-Profit, Other Than Small Business, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirement and in the capability statement paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages. The 10-page limit does not include the cover page, executive summary, resumes, or references, if requested. Any business concerns that believe they possess the capability necessary to successfully undertake the work described above must SUBMIT CAPABILITY STATEMENTS ELECTRONICALLY to the Contract Specialist, Shaun Rostad at Shaun.Rostad@nih.gov, NO LATER THAN 1:00 p.m. EST on November 20, 2026. The Subject line for the submission should include this Sources Sought Number, SAM.gov Unique Entity Identifier (UEI) and organization name. NIDA will not accept paper or faxed capability statements. THIS NOTICE IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. CONFIDENTIALITY. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
-Market Research11/20/2026
See attached Sources Sought Notice and attached Draft Statement of Work. SOURCES SOUGHT NOTICE Solicitation Number: 75N98027R00005 Title: Quantitative Analysis of Longitudinal MR Images Classification Code/Title: AN11 - Health R&D Services; Health Care Services; Basic Research NAICS Code/Title: 541714 Research and Development in Biotechnology (except Nanobiotechnology) Size Standard: 1,000 employees Description: This is a Research and Development (R & D) Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential R & D requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Small businesses are encouraged to respond. Background: Since 1958, the Baltimore Longitudinal Study of Aging (BLSA) has been a major research program conducted by the National Institute on Aging (NIA). The BLSA is a multi-disciplinary study of physiologic and psychological aspects of normal aging in community-dwelling men and women. Active BLSA participants are volunteers who visit the Clinical Unit of the NIA-Intramural Research Program (IRP) in Baltimore, MD for testing every 1 to 4 years. Since 1994, the NIA has been conducting a longitudinal brain imaging study of older adults in the BLSA to characterize individual differences in longitudinal brain changes, to investigate the extent to which these brain changes underlie individual differences in cognitive aging, to identify brain changes that may be predictors of cognitive decline and Alzheimer’s disease, and to assess the impact of potential modulators of brain and cognitive aging. As of October, 2024, more than 4000 neuroimaging evaluations have been performed for BLSA participants. As part of this research program, it has also been necessary to develop and validate sophisticated tools for analysis of longitudinal neuroimaging data that can be applied in large-scale studies. Thus, this project has involved the development, validation, and refinement of novel image analysis tools and the application of these tools to longitudinal Magnetic Resonance (MR) imaging scans and Positron Emission Tomography (PET) measures of regional cerebral blood flow, amyloid and tau deposition in brain. More recently, these tools include advanced machine learning approaches using pattern analysis to classify clinical status and aging trajectories of individuals based on structural and functional brain images. The work of this requirement will continue to focus on the application of sophisticated tools and quantitative analysis of longitudinal MRI data acquired from BLSA participants. Thus, the proposed contract will apply methods developed in prior acquisitions, that allow continuity of research and provide longitudinal consistency of measures of global and regional brain volumes and ischemic lesion volumes, as well as functional MR data, including consistency with MR data acquired during earlier phases of this project (since 1994). This Contract will also require the application of sophisticated analytic approaches, including previously developed machine learning and pattern analysis methods, to allow classification of risk for cognitive impairment and likelihood of maintenance of cognitive resiience on an individual subject basis. Purpose and Objectives: The principal goal of this procurement is to provide quantification of MR imaging scans to provide measures of brain structure and function in BLSA participants, including heterogenous brain aging trajectories. Specifically, these data will allow NIA investigators to continue to address the following questions: What are the rates and regional distribution of changes in brain anatomy in non-demented men and women throughout adulthood? What is the frequency and progression of brain abnormalities in older adults and what is the clinical significance of these findings for cognitive aging? Against a background of age-related changes in brain structure, which changes predict cognitive impairment and Alzheimer’s disease, and conversely, what are the predictors of the maintenance of cognitive health or cognitive resilience? What factors modulate cognitive and brain aging and how do they impact brain-behavior associations? Project Requirements: See attached Draft Statement of Work. Anticipated Period of Performance: The anticipated period of performance is one year from date of award. Capability Statement/Information Sought: Companies that believe they possess the capabilities to provide the required products should submit documentation of their ability to meet each of the project requirements to the Contracting Officer. The capability statement must specifically address each of the project requirements separately. Additionally, the capability statement should include 1) the total number of employees, 2) the professional qualifications of personnel as it relates to the requirements outlined, 3) any contractor GSA Schedule contracts and/or other government-wide acquisition contracts (GWACs) by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Capability statements must also include the Company Name, Unique Entity ID from SAM.gov, Physical Address, and Point of Contact Information. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. Interested companies are required to identify their type of business, applicable North American Industry Classification System (NAICS) Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Sneha Singh, Contract Specialist at e-mail address sneha.singh@nih.gov. The response must be received on or before Monday, November 9, 2026, 9:00 AM, Eastern Time. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in betaSAM. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
-Market Research11/09/2026
Synopsis: This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources to perform a potential requirement; (2) whether they are small businesses; 8(a) small businesses, service-disabled veteran-owned small businesses; veteran-owned small businesses; women-owned small businesses; HUBZone small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification system (NAICS) code for the potential acquisition. Your responses to the information requested will assist the government in determining the appropriate acquisition method, including whether a small business set aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. The requirement is assigned a code of 541715 in the North American Industry Classification System (NAICS), and the small business size standard for such requirements is 1,000 employees or less. This notice is issued for market research purposes to assess potential small business sources, industry practices, and the availability of commercial services. The Government has not made a final determination regarding acquisition strategy, contract type, commerciality, or small business set-aside status. Respondents should identify whether they can perform the requirement as a prime contractor, including through existing teaming arrangements or qualified subcontractors, and distinguish their own capabilities from those of proposed team members. Background: The National Institute on Minority Health and Health Disparities (NIMHD) conducts and supports research and training programs to advance knowledge and understanding of health disparities, identify mechanisms to improve minority health and reduce health disparities, and develop effective interventions in community and clinical settings. NIMHD is the lead organization at the National Institutes of Health (NIH) for planning, reviewing, coordinating, and evaluating minority health and health disparities research activities. NIMHD also promotes workforce development, supports research capacity at less-resourced institutions that train students in research careers, serves populations experiencing health disparities, supports participation in clinical research, and promotes information dissemination through regular communications, public education outreach, and scientific presentations. The President’s Executive Order (EO) 14212 Establishing the President’s Make America Healthy Again Commission aims to improve the health of Americans. As described in the EO, escalating burden of chronic diseases poses significant challenges in the United States. These conditions contribute to rising health costs, reduced workforce productivity, and stagnant life expectancies across the country, both in adults and children. NIH defines a health disparity as a measurable difference in health that exists between specific population groups. This is a rigorously derived and data-driven determination operationalized by quantifiable metrics, rather than a statement of attribution. It is a scientific starting point that identifies where health outcomes diverge, not a predetermined conclusion about why. Scientific investigations to identify or understand the root causes are separate and distinct scientific questions, which are necessarily multifaceted and complex. NIH funded research is interested in those health disparities that are modifiable or actionable to improve the health of all population groups. Health disparities may be observed in the risks, prevalence, or problems resulting from specific behaviors, as well as the incidence, prevalence, and mortality from conditions, diseases, and/or disorders. To fulfill the NIH mission of seeking fundamental knowledge about the nature and behaviors of individuals as living systems, and the statutory purpose of NIMHD, to conduct research to understand and reduce health disparities, NIMHD Division of Intramural Research (DIR) conducts population health research to understand how health outcomes vary across populations, identify multilevel modifiable factors that drive these disparities, and develop, test, and evaluate clinical and population-based interventions to reduce these disparities. NIMHD DIR requires contractor assistance to provide R&D social and behavioral sciences research services to support NIMHD DIR in conducting population health and clinical research to understand and reduce health disparities in the United States. The Government anticipates that individual task orders may involve differing research designs, study populations, sites, durations, and levels of complexity. Interested firms should explain their ability to mobilize qualified personnel and research resources for multiple concurrent studies as requirements arise. NIMHD is seeking small businesses capable of designing, conducting and overseeing the clinical, scientific, and technical aspects of investigations into health disparities across populations, to identify modifiable risk and protective factors associated with these disparities, and develop and test interventions to reduce these disparities. Study designs to be used may include, but are not limited to: Population-based cross-sectional surveys; Epidemiological studies (e.g., longitudinal cohort study, case-control studies); Clinical trials; Community-based intervention studies; Simulation modeling; and Qualitative research methods (e.g., direct observations, in-depth interviews, focus groups discussions). Independently and not as an agent of the Government, the Contractor shall furnish all necessary services, qualified personnel, material, equipment, and facilities not otherwise provided by the Government to successfully perform the requirements stated below. Specifically, the Contractor shall, as required by individual task orders, perform the following technical requirements summarized below that also are included in the attached Draft Statement of Work (SOW), including but not limited to: Provide personnel, facilities, and other services necessary to maintain and coordinate multiple health disparities research studies funded through task orders under this Indefinite Delivery, Indefinite Quantity (IDIQ) contract. Provide overall project management and coordination of activities performed under individual task orders, including development and maintenance of project plans, schedules, milestones, coordination of participating research sites and subcontractors, monitoring of performance, identification and resolution of project risks and issues, and preparation of progress reports as specified in the applicable task order. Conduct research studies through qualified organizations, as specified in individual task orders, and receiving consent from the Contracting Officer’s Representative (COR) and Contracting Officer (CO). This includes (but is not limited to) implementation of protocols; population health and clinical research site monitoring; regulatory compliance assurance; and analyses of data from clinical, laboratory, population and epidemiologic studies. Provide and manage participating population health research and clinical trial sites, investigators, laboratories, and other research resources necessary to conduct studies, directly or through qualified subcontractors. The Contractor shall draft, negotiate, execute, administer, monitor, renew and/or modify as necessary, subject to subcontractor's satisfactory past performance, and with the consent of the CO, subcontracts with domestic population health studies, clinical research sites and laboratories, and provide support for these population health studies, clinical research site and laboratories. The Contractor shall assume responsibility for population health and clinical sites, including site readiness to start new research studies. This includes the establishment of new subcontract agreements for these sites (including laboratories), data management, and other operations and functions. As existing protocols close, the Contractor shall assume responsibility for any new protocols at these sites. Recruit and retain numbers of potential research subjects sufficient for the timely completion of all protocols. Provide United States based investigators in the United States with expertise in the population health and clinical care, to conduct protocols specified through individual task orders. Provide professional and technical staff adequate to provide scientific and administrative coordination of multiple population health and clinical health disparities research studies. These staff shall include, but are not limited to, qualified medical, nursing, and neuropsychologic staff, study coordinators, personnel for participant identification, recruitment, study conduct, and retention, pharmacists, and laboratory technicians. Ensure sites have access to populations of interest, laboratory facilities with the capability to perform clinical research specified in task orders. Identify and engage community organizations, community leaders, health care providers, and other relevant stakeholders; establish and support community advisory boards, community coalitions, or other partnerships; conduct community needs and readiness assessments; and facilitate community participation in research planning, implementation, and dissemination of findings. Develop and implement quantitative and qualitative data collection methods, including surveys, interviews, focus groups, direct observations, and other methods appropriate to the research protocol. The Contractor shall manage, analyze, and report data collected through these methods, as required by individual task orders. Provide facilities and equipment adequate to conduct population health, inpatient and outpatient clinical research studies. Equipment purchases must be approved by the COR and CO. Ensure that sites have (through lease or direct provision, if required) electronic information systems compliant with the Federal Information Security Modernization Act (FISMA), necessary specialized equipment (including hardware and software) for sites to electronically communicate with the Contractor, subcontractors, and NIMHD DIR as required, for processing and storage of biospecimens (e.g., ultralow temperature freezer, specialized shipping materials and training for shipment of biohazardous materials and dangerous goods, and for receipt, storage, monitoring, and dispensing of investigational drugs). Obtain access for research protocol review and approval (or exemption) to a standing Institutional Review Board (IRB) and ensure that each institution conducting population health and clinical research studies has a current, approved Federal-Wide Assurance Number on file with the Office for Human Research Protections (OHRP). Ensure that all the staff at each site participating in the design or conduct of population health and clinical research involving human subjects, complete and maintain education on the human research protections. Ensure that when appropriate, population health and clinical research sites have a community advisory board (CAB) constituted with members of the local community that can provide community perspective and advice for science in the community where the population health and clinical research is located and that provides community input. The Contractor shall provide services to ensure regulatory compliance for research activities including subcontracted sites' performance. More specifically: Ensure site access to a communications system in compliance with U.S. Food and Drug Administration (FDA) requirements for the submission of Adverse Experience Reports (AERs) by Subcontractors to the Contractor for transmission as required to the COR as required. Monitor the accuracy of adverse experience reporting through regular summary reports for submission to the COR. Draft safety reports as required by the FDA for selected studies for COR Submission. Develop, implement, and monitor plans for acquisition, distribution, dispensing, handling, administration, and accountability of study interventions (pharmaceutical and non-pharmaceutical), in compliance with applicable Federal, state, and local regulations. Provide site monitoring for quality assurance of research conducted at all clinical and laboratory sites, as designated by the COR. Monitoring schedules shall be approved by and results reported to the COR with a copy to the CO and shall include assurance of compliance with FDA record keeping and reporting requirements (21 CFR 50 and 56; 21 CFR 312.50, Subpart D), accuracy and completeness of case report forms, source documentation, and other research records, and periodic record auditing and documentation by the staff of the subcontracted centers. Each site shall be visited a minimum of 2-3 times annually. Provide staff with laboratory expertise and assist in monitoring clinical trials site laboratory quality with the COR and NIMHD Quality Assurance (QA) programs. Meet with the NIMHD program and contracting staff to review annual site performance and monitoring reports for participating population health and clinical research sites. The Contractor shall provide population health, clinical and statistical analysis and reports. More specifically: Provide scientific, technical, and administrative support for the development, implementation, and analysis of the specified research, including considerations of experimental design, sample size calculation, and interim and final primary and secondary analyses specified by study protocols, as requested by the COR. Establish data elements to be recorded by the protocol research records, as requested by the COR and in conjunction with the protocol development team for each specific research project. Develop study forms for standardized collection of data items. Develop documentation and coding for computerization of data for retrieval, analysis, and reporting. Provide for timely and accurate data collection and submission, data entry, data quality assurance, retrieval of source documentation, and generation of data and safety monitoring reports. Provide training for staff of population health, clinical and laboratory sites in data management procedures. Provide data input, editing, electronic data storage, database management, data retrieval, and statistical analysis using well-documented database management and statistical computer software programs. Develop methodology, perform analyses, and provide results from meta-analyses of selected data sets derived from population health and clinical research studies that focus on health disparities. Provide data analysis and results. More specifically: Perform statistical analyses of study data to test study hypotheses and evaluate potential confounding variables and/or covariates, as requested by the COR. Data analytic techniques needed include approaches to analyzing multiple measurements of biologic variables over time within participants and between participant groups, with consideration for normal changes in these variables with demographics. Provide for biweekly to monthly communication, as needed, of analytic progress and results through routine meetings (the majority to be virtually) with COR or designees and periodic generation of reports. The Project Manager shall attend all meetings. The Epidemiologist, Statistician, and Senior Systems Analyst shall attend these meetings on an as needed basis dependent upon the PI’s request. Provide programming and statistical support adequate for the timely generation of additional analyses requested by the COR. Provide electronic data transmission between the Contractor, population health, clinical and laboratory sites, and NIMHD DIR using currently specified communications software and equipment. Provide for electronic mail transmission between the Contractor, population health, clinical and laboratory sites, and NIMHD DIR using commercially available communications software and equipment. Provide protocol development services and assistance. The Contractor shall provide services for the implementation and monitoring of multiple population health and clinical research studies. More specifically: Develop, initiate and coordinate implementation and oversight of protocols at all participating population health, clinical and laboratory sites designed by the COR and approved by the CO. Ensure compliance by sites with all requirements for protocol implementation, including IRB review and approval prior to protocol initiation, participant consent, and confidentiality requirements, and Federal bioresearch regulations and requirements for security and confidentiality of research records, and that each relevant population health and clinical research site staff member completes and maintains human research protection and Good Clinical Practice training, when appropriate. Draft, negotiate, execute, administer, monitor, renew and/or modify as necessary with approval by CO a site-specific, protocol-specific budget for each protocol to be conducted by population health, clinical and laboratory sites, based on the anticipated number of participants to be enrolled. Provide training for staff of clinical and laboratory centers in procedures for implementation and conduct of specific protocols. Retraining may be required to be performed as necessary. Provide training in and ensure the fulfillment and maintenance of standards for Good Clinical Practices (GCP) and Good Clinical Laboratory Practices (GCLP) across population health and clinical research sites and staff, whenever appropriate. Ensure timely development and execution of material transfer agreements (MTAs) and data transfer agreements (DTAs) between the sponsor(s) and population health and clinical research sites. The Contractor shall provide services for the development and review of research activities. More specifically: For specific new protocol topics identified by the COR, identify a protocol development team consisting of Contractor staff, NIH staff, subcontractors, and/or consultants. Provide support for the planning and conduct of protocol development team meetings. Submit at the initial meeting a protocol development plan for COR review and approval, addressing regulatory issues, data collection forms development, drug distribution plan, protocol timeline, and participating sites. Develop a protocol document including background, objectives and endpoints, design, patient numbers, source, management, and selection, study agents or other interventions, clinical and laboratory monitoring, laboratory services, toxicity management, adverse experience reporting, evaluation of response, statistical considerations, data collection and monitoring, human subjects’ considerations, biohazard containment, and data and safety reviews. Review, edit, and rewrite draft protocols based on COR’s review. Prepare and maintain the necessary documentation for application submissions in compliance with FDA requirements. Upon completion of a final protocol, renegotiate subcontractor budgets with the approval of the CO and implement the new protocol at participating sites. For ongoing protocols, provide, at the request of the COR, support for the planning and conduct of meetings of protocol committees and subcommittees, data and safety monitoring boards, and investigators. Provide administrative, technical, and logistical support at the request of the COR and with approval of the CO as needed for interaction and collaboration of the Subcontractors with other institutes, agencies, and organizations conducting activities relevant to health disparities research. Support the identification, development, implementation, and evaluation of interventions to improve health outcomes and reduce health disparities, including assessment of feasibility, acceptability, effectiveness, and potential impact. Provide consultants with specialized expertise related to population health and clinical research especially related to health disparities, as requested by NIMHD DIR. Plan, organize, and coordinate meetings involving internal and outside experts. This meeting will be an important venue to discuss important and complex scientific issues related to research protocols and emerging research priorities. Provide support services for ongoing population health and clinical research studies, which include, but are not limited to, the following: site monitoring, subcontract management and invoicing, protocol management, oversight of data management and data analysis, study agent procurement, team meetings, regulatory compliance assurance, site activation and protocol registration, safety monitoring, committee management, data management services, oversight of central and site laboratories and pharmacies, protocol team support, FISMA compliance and IT security, laboratory equipment support, and training of site personnel, to support this effort. Provide Core infrastructure support for ongoing population health and clinical research at the sites, including but not limited to the following: maintenance of IRB/EC regulatory reporting, subject recruitment and follow-up, Community Advisory Board (CAB) support for meetings, protocol updates and reporting, attendance and participation in site monitoring visits, attendance at the annual network meeting, invoicing and other report preparation. Experience coordinating data from all aspects of ongoing protocols, studies, and trials. Experience in initiating and managing 3-6 studies each year. Experience initiating and managing studies of different sizes from approximately 100 participants up to approximately 10,000 participants. Experience working with populations experiencing health disparities, e.g., people in low socioeconomic conditions, living in rural underserved areas, and racial and/or ethnic populations who have documented health disparities based on diseases and conditions. Experience initiating and managing studies with a length in time from a few months for cross-sectional studies to a few years in clinical studies. Experience managing studies of varying complexities from simpler studies, which may be qualitative studies involving in-depth interviews with about 100 people; to more complex studies that involve a multi-site clinical trial with 1-2 years follow-up including biospecimen collection. Commercial Availability of Services – Based on preliminary market research, the Government anticipates that the contemplated research services may be noncommercial in nature. However, interested respondents are encouraged to identify comparable services available in the commercial marketplace. If so, describe which portions of the requirement could be met commercially and which would require customization, integration, or specialized development. Provide supporting information, including customary pricing practices and potential firm-fixed-price arrangements, if available. Industry Feedback on Draft SOW – Respondents are encouraged to provide comments or recommendations on the draft SOW, including opportunities to clarify requirements, improve performance outcomes, identify potential implementation challenges, or incorporate commercially available approaches. Identify any provisions that may unnecessarily limit small business participation and suggest practical alternatives. Any recommendations should identify the applicable SOW section when possible. Anticipated Award Date: The Government expects to award an Indefinite Delivery Indefinite Quantity (IDIQ) contract approximately in September 2027. Disclaimer and Important Notes: This notice does not obligate the government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this Notice. This notice is for information purposes only. CONFIDENTIALITY: No proprietary, classified, confidential, or sensitive information should be included in your response. The government reserves the right to use any nonproprietary technical information in any resultant solicitation(s). Responses and Capability Statements: Interested Small Businesses that believe they possess the capabilities necessary to undertake this project should submit an electronic copy of their capability statement addressing the areas listed above to the attention of Edwin Osorio, Contract Specialist (E-mail: edwin.osorio@nih.gov) and Lisa Schaupp, Contracting Officer (E-mail: lisa.schaupp@nih.gov). Please state clearly in the subject line of the email that it is in response to the Sources Sought notice no.75N94027R00005. Please limit responses to 20 pages or less, exclusive of resumes. Electronic capability statements should be received by the Contracting Officer and Contract Specialist by 4:30 PM Eastern time on November 25, 2026. Respondents must submit their capability statement via electronic submission only. Capability statements must identify the 1) organization name, address, point of contact, contact phone number, and email address; 2) Small Business status of the organization, NAICS code along with SAM.gov Unique Entity Identifier (UEI) and CAGE code, if assigned, size and type of business (e.g., 8(a), HUBZone, etc.). No phone calls will be accepted. The designated NAICS code for this effort is 541715 and the size standard is 1,000 employees or less. Respondents may provide brief SOW comments and commercial availability information within the existing 20-page response limit. The Government may use the information received to refine the draft SOW and acquisition strategy; participation does not preclude responding to any future solicitation.
-Market Research11/25/2026

Additional Details

Solicitation Number

75N95022D00017

Archive Date

Jan 14, 2026

Office Address

Bethesda, MD, 20892